WilmerHale advised the underwriters in Q32 Bio Inc.’s public offering of 6,027,399 shares of common stock and pre-funded warrants to purchase 4,931,506 shares of common stock. Q32 Bio, a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, received approximately $200 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. In addition, Q32 Bio granted the underwriters a 30-day option to purchase up to 1,643,835 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

The WilmerHale team was led by Lisa Firenze and Andrea Sorrentino and included Katharine Patterson, Michaela Rosen, Whitley Horning and Sophie Bonadeo, with assistance from Barish Ozdamar on intellectual property matters, Bruce Manheim on regulatory matters and Ben Kelsey on tax matters.